SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nokomis who wrote (53537)7/28/1999 4:24:00 PM
From: Connor26  Read Replies (2) of 120523
 
BEAM - hopefully this type of info will keep the stock moving - especially the last sentence

Last week the FDA Ophthalmic Advisory Panel recommended approval of the Company's PMA application for treatment of high myopia and high astigmatism with LASIK using the Summit Apex Plus Excimer Laser Workstation. When approved by the FDA, this would give Summit the broadest indication in the US marketplace for the treatment of myopia with or without astigmatism. The FDA also granted Summit an IDE to initiate studies for customized ablations using its patented CustomCornea® measurement device and its LADARVision system. Summit is the only manufacturer to offer a choice of two FDA-approved excimer laser systems.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News